Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
2254 studies found for:    "core binding factor acute myeloid leukemia" OR "Leukemia, Myeloid, Acute"
Show Display Options
Rank Status Study
1 Recruiting Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Intrathecal (IT) cytarabine
2 Recruiting ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Procedure: Tumor sampling;   Biological: Constiutional DNA sampling
3 Recruiting Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Procedure: FDG-PET/CT guided bone marrow sampling
4 Unknown  Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
Condition: Leukemia, Myeloid, Acute
Intervention: Procedure: Allogenic transplantation
5 Recruiting A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: CC-90009
6 Terminated Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Troxatyl™ (troxacitabine)
7 Active, not recruiting SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: SGI-110 (guadecitabine);   Drug: Treatment Choice
8 Recruiting Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Quizartinib
9 Completed Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: AC220
10 Completed A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AC220;   Drug: daunorubicin;   Drug: cytarabine
11 Completed Oral Clofarabine for Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Clofarabine
12 Completed A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: AC220
13 Recruiting A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AG-120;   Drug: Azacitidine;   Drug: AG-221
14 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
15 Completed
Has Results
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Lenalidomide;   Drug: Azacitidine
16 Recruiting A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Azacitidine;   Other: Control Arm
17 Completed
Has Results
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: G-CSF;   Drug: Plerixafor;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
18 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
19 Completed Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Volasertib
20 Completed Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine;   Drug: Bexarotene

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.